83 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Article Searches
Bristol Myers (BMY) Reports Positive Data on Breyanzi, Opdivo https://www.zacks.com/stock/news/2283577/bristol-myers-bmy-reports-positive-data-on-breyanzi-opdivo?cid=CS-ZC-FT-analyst_blog|company_news_medical_sector-2283577 Jun 04, 2024 - Bristol Myers (BMY) announces positive data from three studies evaluating CAR T cell therapy Breyanzi (liso-cel) and three updated analyses on studies evaluating Opdivo at ASCO.
Bristol Myers (BMY) Gets EC Nod for Opdivo Label Expansion https://www.zacks.com/stock/news/2281590/bristol-myers-bmy-gets-ec-nod-for-opdivo-label-expansion?cid=CS-ZC-FT-analyst_blog|company_news_medical_sector-2281590 May 30, 2024 - Bristol Myers' (BMY) Opdivo combination regimen receives the European Commission's approval for the first-line treatment of unresectable or metastatic urothelial carcinoma.
Prothena (PRTA), Bristol Myers Tie Up for Second Neuro Candidate https://www.zacks.com/stock/news/2280718/prothena-prta-bristol-myers-tie-up-for-second-neuro-candidate?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2280718 May 29, 2024 - Prothena (PRTA) announces that Bristol Myers is exercising its option for the second time, thereby in-licensing exclusive global rights for PRX019 to potentially treat neurodegenerative diseases.
Bristol Myers (BMY) Updates Action Date for Subcutaneous Opdivo https://www.zacks.com/stock/news/2277541/bristol-myers-bmy-updates-action-date-for-subcutaneous-opdivo?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2277541 May 22, 2024 - The FDA assigns a new target action date of Dec 29, 2024, to Bristol Myers (BMY) BLA for subcutaneous nivolumab (nivolumab and hyaluronidase).
Biotech Stock Roundup: NVAX, FULC Up on Deals With SNY, Updates From MRNA, BMY https://www.zacks.com/stock/news/2275062/biotech-stock-roundup-nvax-fulc-up-on-deals-with-sny-updates-from-mrna-bmy?cid=CS-ZC-FT-analyst_blog|stock_roundup-2275062 May 16, 2024 - Novavax, Inc (NVAX) and Fulcrum Therapeutics, Inc (FULC) are in the spotlight following license agreements with pharma giant Sanofi.
Bristol Myers (BMY) Fails to Meet Goal in Opdivo NSCLC Study https://www.zacks.com/stock/news/2272954/bristol-myers-bmy-fails-to-meet-goal-in-opdivo-nsclc-study?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2272954 May 13, 2024 - Bristol Myers' (BMY) late-stage label-expanding study evaluating the Opdivo/Yervoy combination fails to meet the primary endpoint of progression-free survival in unresectable stage III NSCLC.
2 Beaten-Down Stocks to Buy and Hold for 10 Years https://www.fool.com/investing/2024/05/10/2-beaten-down-stocks-to-buy-and-hold-for-10-years/?source=iedfolrf0000001 May 10, 2024 - They offer plenty of upside and solid dividend growth.
A Look at Pharma ETFs Post Q1 Earnings https://www.zacks.com/stock/news/2269782/a-look-at-pharma-etfs-post-q1-earnings?cid=CS-ZC-FT-etf_news_and_commentary-2269782 May 07, 2024 - Many industry bigwigs reported solid results, with some beating on earnings or revenues or both.
Biotech Stock Roundup: BIIB, BMY's Q1 Earnings, INCY's Acquisition & Updates from VRTX https://www.zacks.com/stock/news/2262685/biotech-stock-roundup-biib-bmy-s-q1-earnings-incy-s-acquisition-updates-from-vrtx?cid=CS-ZC-FT-analyst_blog|earnings_article-2262685 Apr 25, 2024 - Biogen (BIIB) and Bristol Myers (BMY) are in focus following Q1 earnings announcement.
Bristol Myers (BMY) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates (Revised) https://www.zacks.com/stock/news/2262549/bristol-myers-bmy-q1-earnings-taking-a-look-at-key-metrics-versus-estimates-revised?cid=CS-ZC-FT-fundamental_analysis|nfm-2262549 Apr 25, 2024 - While the top- and bottom-line numbers for Bristol Myers (BMY) give a sense of how the business performed in the quarter ended March 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Pages: 123456789

<<<Page 4>